Marfan Sartan: a randomized, double-blind, placebo-controlled trial. - sprookjes - yvandenbroek - TriplyDB

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q48083985

about

A Case Based Approach to Clinical Genetics of Thoracic Aortic Aneurysm/Dissection.Marfan syndrome: current perspectives Long-term miR-29b suppression reduces aneurysm formation in a Marfan mouse model.The Genetics of Aortopathies in Clinical Cardiology.The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations The year in cardiology 2015: peripheral circulation.Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24-32.Marfan Syndrome and Related Disorders: 25 Years of Gene Discovery.Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall.Sudden death due to aortic pathology.Aetiology and management of hereditary aortopathy.The spectrum of spontaneous coronary artery dissection: illustrated review of the literature.Aortic events in a nationwide Marfan syndrome cohort.Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models.NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome.Strategies to prevent aortic complications in Marfan syndrome.Association between malignancies and Marfan syndrome: a population-based, nested case-control study in Taiwan.AP-1 Oligodeoxynucleotides Reduce Aortic Elastolysis in a Murine Model of Marfan Syndrome.Beta-blockers for preventing aortic dissection in Marfan syndrome.Crossing Bridges between Extra- and Intra-Cellular Events in Thoracic Aortic Aneurysms.The Effect of a Non-peptide Angiotensin II type 2 receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death.Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.Marfan and Sartans: time to wake up!2017 ESC/EACTS Guidelines for the management of valvular heart disease.Atherosclerosis, neoatherosclerosis, and vascular disease.Deregulated microRNA and mRNA expression profiles in the peripheral blood of patients with Marfan syndrome.Angiotensin, transforming growth factor β and aortic dilatation in Marfan syndrome: Of mice and humans.High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations

P2860

Q26744537-6920147A-89E7-4452-8D88-9CE945551EC8 Q26747739-172E3056-9C25-47D0-B8D2-120CD0E977F0 Q33612367-AAFC7E98-A4A2-44E2-BBAE-E243D89CC074 Q33758342-BBA03F55-C452-489D-B4B7-98F3139AD039 Q37341800-F86140FA-407C-4E1F-B78E-EBA1E6A06B76 Q38685687-0C1B8742-5DBD-4AB5-8C2A-322954453F02 Q38706381-EA63FA40-A177-4988-9A7D-684A8E9E828A Q38751533-A621B0CE-07FD-456F-9FB3-60BA5EBCFA5F Q38930482-CE0C3ABA-48F8-40DF-8B0E-9104B0D2926C Q39085595-9DB66286-141F-4549-8162-7F6CCD763824 Q39094762-16EFB85C-8E0C-4ECE-8504-0D66CD200445 Q39402194-5112E045-166E-44EF-857A-CDF4B58B1B12 Q39464795-3260A950-5A7D-4B9A-9CF6-875416F627C4 Q39694748-7E3B0035-6843-49EA-B404-48DF103CBDB5 Q40952704-BD0EE37C-AAB3-48F6-8B11-91CC8670AD8B Q42230262-29986E7A-73C8-4523-A7AC-23F823B78706 Q42341364-86931DE3-0795-47A2-81CA-5E5E9091097B Q42650213-012BB711-B256-4854-BD3A-860FE2860E82 Q47104189-02B9E0D2-DA18-4ABA-8D90-860AFBFF494E Q47645094-BCCBA9D4-28F7-4D68-9C01-36728E85A79C Q47751472-EC81CE48-67B2-41FF-A9B2-55DEEB38D563 Q47752010-9308149B-4D95-4877-8C6C-50A700CF0FCF Q48194218-FC610A1A-673E-4C46-9814-E1A6BDC541E6 Q49083618-FD273EDA-10EB-4425-AA85-DAFB503C9205 Q49134981-5A777370-065F-4B04-B90A-5713AD12EFCA Q50196541-DE09256F-7827-4A9E-BB2F-762CACA22B97 Q51799316-521A7384-19DC-4938-981F-8EFEAB1E32D4 Q54940461-B0A0BC18-AC95-4DCB-9D3D-91F849D71EA6 Q55266983-E7270E61-92E7-46AF-AB68-623F927956A6 Q57244819-AEC02721-E82F-46C0-B80D-9BF03CF8F021

P2860

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q48083985

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

@en

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

@nl

type

label

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

@en

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

@nl

prefLabel

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

@en

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

@nl

P1433

Q48083985-2F457B51-5BEC-4E87-B047-49D3F0138B0C

P1476

Q48083985-0F0C3E86-869A-4757-8992-5D1596F8F856

P2093

Q48083985-0FFADB98-4EFF-47A8-AD10-39298FBA5800

Q48083985-1DB32B7B-6F63-4553-AB02-6C9D0D1DAEA4

Q48083985-2302164D-73B3-46D1-AC64-033153952D75

Q48083985-26FB4E77-AF84-4B2C-93C4-64B26B0318B3

Q48083985-3A1B5315-0122-4723-BE9E-6E5FFD80735C

Q48083985-3A2E143E-75FD-492D-92E0-9FBD9B58ABBD

Q48083985-3B95DCF9-9705-42C5-A83A-A8F273C3B305

Q48083985-47E256B0-0C2B-4DB2-A14E-4D48F487D0B2

Q48083985-6B14BA6F-40E8-43C8-883D-2CB859076C13

Q48083985-77EEAF6B-B252-4938-A3F3-F8FCA3D24053

P2860

Q48083985-04A9A6D9-9EBA-4E1F-8ED6-BCA07E4FB216

Q48083985-06FD407B-9A7C-4E0D-AA68-92069F25117C

Q48083985-07F575F3-ED22-4D12-8940-FDCEB55A4F21

Q48083985-1273E1CD-B9D0-4B9B-AED8-C855EBD1937E

Q48083985-1FDEF77B-481C-4A29-A9AA-A624B40F8ADC

Q48083985-201D284A-2016-4024-9154-A524337A6D98

Q48083985-21E85DB8-B166-4697-9DFC-5D80EB5C8294

Q48083985-26A99192-10EC-462C-931C-FD42FFD3DA69

Q48083985-26A9C919-20B0-4BFB-A8D2-7C2EEDF8A515

Q48083985-30F174E7-E0E9-43D1-9DFA-9CD80A40A541

P304

Q48083985-633DAA13-6E99-4EB3-80E7-4E47CA2F97D9

P31

Q48083985-37D364C9-A7E8-459C-8C3C-CFB2E6DBD4CA

P356

Q48083985-A11C4B9A-EE53-4A0C-ACD4-F63C7B675247

P433

Q48083985-9876EF1D-F5D4-408E-B052-5DCAFEAA71CB

P478

Q48083985-A578D4E4-3E07-4618-ABF7-ED5A11E9A127

P50

Q48083985-109359DB-9A5C-48F7-B0E7-2BD1BC79D0BA

Q48083985-27B4D4CB-57A8-465A-A98E-D7FBBBC5E0F2

Q48083985-28DC8B4F-D21A-4E7C-A53E-076978C34ADA

Q48083985-7D448AF4-C8DE-4CC5-B256-AC8E979A539F

Q48083985-8EACCCC5-2927-4A8F-BE6F-D21387509DE7

Q48083985-B83D2369-E893-43E8-A591-2F9A43FCFBAF

P577

Q48083985-EE6D3DCE-E4CB-40B0-9BC0-3E9E9DB0DF74

P5875

Q48083985-31400F24-883D-4E32-96AC-21979EA000B5

P698

Q48083985-D4CE7B98-E621-42B4-AB4A-48DD28E1E387

P921

Q48083985-17967F1C-8A05-4471-A8CD-5CC65BA486EB

P356

P1433

European Heart Journal

P1476

Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

@en

P2093

Adeline Basquin

http://www.w3.org/2001/XMLSchema#string

David Attias

http://www.w3.org/2001/XMLSchema#string

Delphine Detaint

http://www.w3.org/2001/XMLSchema#string

Florence Arnoult

http://www.w3.org/2001/XMLSchema#string

Florence Tubach

http://www.w3.org/2001/XMLSchema#string

Francois Sassolas

http://www.w3.org/2001/XMLSchema#string

Gabriel Delorme

http://www.w3.org/2001/XMLSchema#string

Guillaume Jondeau

http://www.w3.org/2001/XMLSchema#string

Henry Plauchu

http://www.w3.org/2001/XMLSchema#string

Jean-Eric Wolf

http://www.w3.org/2001/XMLSchema#string

P2860

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index

A controlled trial of renal denervation for resistant hypertension

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome

The revised Ghent nosology for the Marfan syndrome

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideli

Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.

Atenolol versus losartan in children and young adults with Marfan's syndrome.

Effects of arterial stiffness, pulse wave velocity, and wave reflections on the central aortic pressure waveform.

P304

2160-2166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHV151

http://www.w3.org/2001/XMLSchema#string

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Sophie Dupuis-Girod

Philippe Aegerter

Catherine Boileau

P577

2015-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275772362

http://www.w3.org/2001/XMLSchema#string

P698

25935877

http://www.w3.org/2001/XMLSchema#string

P921